BPC-157 Cycle Guide

What Is a BPC-157 Cycle?

A cycle is a continuous period of daily BPC-157 use followed by a discontinuation period (break). Unlike hormones that require post-cycle therapy or mandatory breaks due to receptor downregulation, BPC-157 does not create dependence or suppression of endogenous systems. Cycling is more about optimization—allowing tissue remodeling to complete and resetting the body's regenerative baseline—than about preventing long-term toxicity.

Typical pattern: 8 weeks on, 4 weeks off, repeat as needed. Some users do 6 weeks on, 2 weeks off. Others do 4 weeks on, 2 weeks off. Variation is based on injury type, response, and personal preference. The key principle: use BPC-157 for a defined period toward a specific healing goal, then stop and assess progress.

Cycle Length by Injury Type

Acute Injury (Muscle Strain, Acute Tendon Tear)

Cycle length: 4-6 weeks. Acute injuries show rapid response to BPC-157; most functional recovery occurs in the first 4-6 weeks. Extended cycles beyond 6 weeks add minimal benefit for purely acute conditions. Typical protocol: BPC-157 daily for 4-6 weeks, assess pain and function at week 6, discontinue if satisfied. Restart if plateau occurs after 2-3 week break.

Subacute Injury (Partial Tear, Surgery Recovery)

Cycle length: 6-8 weeks. Post-surgical recovery spans 6-12 weeks naturally. BPC-157 for 6-8 weeks covers the critical acute/subacute remodeling window. Discontinue and monitor for additional 4+ weeks to allow complete tissue maturation. Restart if recovery plateaus or return-to-activity goals aren't met.

Chronic Condition (Chronic Tendinopathy, Arthritis, Old Injury)

Cycle length: 8-12 weeks. Chronic conditions have deeper tissue damage and deconditioning. Longer cycles allow deeper remodeling and adaptation. Some users run 12-week continuous cycles for severe chronic injuries. After 12 weeks, take a 3-4 week break for the body to stabilize gains, then restart if further improvement is needed.

Maintenance/Preventive Use

Cycle length: variable. Preventive use (treating a previous injury to maintain durability, or athletes using BPC-157 for optimization) is less defined. Some athletes use 4-week cycles quarterly (4 weeks on, 12 weeks off). Others use 2-3 weeks on with longer breaks. Duration depends on whether the goal is acute healing (shorter cycle) or baseline enhancement (variable, often shorter cycles with longer breaks).

Standard Cycling Protocol

The 8-Week / 4-Week Break Protocol

This is the most common approach and a reasonable default:

Weeks 1-8: BPC-157 daily (250-500mcg, 1-2x daily). Monitor pain, swelling, function weekly. Document progress (photos, range of motion, load tolerance).

Week 8: Reassess. If goals are met (pain resolved, 90% mobility restored, return-to-activity achieved), discontinue.

Weeks 9-12: Off-cycle (4-week break). Tissue continues remodeling post-peptide. Maintain mechanical stimulation via physical therapy, light activity, and progressive loading to consolidate gains.

Week 12 reassess: If fully recovered, consider staying off. If plateau or remaining deficit, restart a second cycle.

Repeat if needed: After 4-week break, resume for another 8-week cycle if progress is inadequate or injury is severe.

The 6-Week / 2-Week Break Protocol

Some users prefer tighter, more frequent cycles:6 weeks on, 2 weeks off. Advantage: frequent reassessment and flexibility. Disadvantage: shorter breaks don't allow full tissue maturation. Better for mild injuries or athletes wanting optimization without long downtime.

The 12-Week Continuous Protocol

For severe injuries or chronic conditions, some users run 12 weeks continuously without a break, then stop and reassess. Advantage: deep, sustained healing window. Disadvantage: longer total disruption to normal biology, higher cumulative exposure. Use only for severe injuries that warrant this commitment.

Determining When to Stop a Cycle

Success Indicators (Stop the Cycle)

Pain resolved or near-baseline (pain 0-2/10 vs baseline 8/10). Swelling resolved or minimal. Full or near-full range of motion restored. Return-to-activity achieved (can walk, run, lift, perform sport without pain or functional impairment). Imaging (if obtained) shows structural improvement (tendon continuity restored, edema resolved, bone callus formation). These indicate healing success; discontinuing allows consolidation without further peptide input.

Plateau Indicators (Continue or Reassess)

Progress present but slow after 6-8 weeks (pain reduced 30-50% but not resolved, swelling decreased but persists, mobility improving but not complete). In this case, continue for weeks 8-12 to push toward full recovery. If plateau is reached and no further progress is evident despite BPC-157, consider that a ceiling has been hit. Discontinue, reassess, and try other approaches (physical therapy intensification, different modality).

Non-Response Indicators (Stop the Cycle)

No improvement after 4-6 weeks of consistent BPC-157 use (pain unchanged, swelling unchanged, function unchanged). This suggests non-responsiveness. Continuing BPC-157 is unlikely to help. Stop, reassess, and consider alternative approaches or underlying issues (disease progression, inadequate immobilization, missed structural damage). Some individuals are non-responders; recognize this and adjust strategy.

Multiple Cycles and Re-Treatment

Back-to-Back Cycles

Restarting BPC-157 after a 2-4 week break is safe based on available data. No evidence of tolerance or diminishing returns with repeat cycles. Some users find second and third cycles equally effective as the first. Others report diminishing efficacy, likely reflecting the fact that healing capacity decreases with each successive cycle (you can't infinitely improve damaged tissue—there's a biological ceiling).

Spacing Between Cycles

A 2-4 week break between cycles is standard. This allows tissue consolidation and gives the body a window to assess the outcome of the previous cycle. Shorter breaks (days-1 week) are acceptable but don't add value. Longer breaks (8+ weeks) are fine if you don't need another cycle yet.

Total Annual Exposure

Most users limit themselves to 12-24 weeks of BPC-157 per year (3-6 cycles of 4-8 weeks each, spaced 2-4 weeks apart). This is a conservative approach based on lack of long-term human safety data. Theoretically, you could cycle indefinitely (year-round on/off), but no evidence supports this as safe or necessary. Let injury healing goals drive cycle frequency, not arbitrary schedules.

Can You Skip the Off-Cycle and Use BPC-157 Indefinitely?

Technically, no evidence shows toxicity from continuous BPC-157 use. Animal studies at high doses for extended periods show no organ damage or adverse effects. However, this is not human data, and long-term safety has not been formally evaluated. Indefinite use assumes a safety profile that is not yet proven.

Practical answer: don't use BPC-157 indefinitely. Use it cyclically for specific healing goals, discontinue, reassess, and restart only if additional treatment is needed. This minimizes total exposure, allows monitoring of efficacy (you discover if it's still working after a break), and preserves the option for future cycles if injury recurs years later. Keeping total lifetime exposure low is prudent when long-term safety is unknown.

Adjusting Cycles Based on Age and Health

Young Adults (18-40)

Faster healing baseline. Shorter cycles (4-6 weeks) are often sufficient. Recovery occurs quickly post-peptide. Standard 8-week / 4-week break protocol works well.

Middle-Aged (40-60)

Moderate healing capacity. 6-8 week cycles typical. May need additional 1-2 cycles for complete recovery. Standard cycling protocols apply.

Older Adults (60+)

Slower healing baseline. 8-12 week cycles recommended. More cycles may be needed for comparable recovery. Expect slower post-cycle tissue maturation; breaks between cycles should be at least 3-4 weeks to allow consolidation. Monitor for side effects more closely.

Comorbidities

Diabetes, poor nutrition, sedentary lifestyle, and other factors impair healing. Longer cycles (8-12 weeks) and additional supportive care (physical therapy, nutritional optimization) are warranted. Do not assume a single BPC-157 cycle will overcome systemic healing barriers; address the underlying factors simultaneously.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions

Can I cycle BPC-157 year-round without breaks?

No evidence supports this. Theoretical risk exists, and no benefit is proven. Use cycles for specific healing goals, then stop and assess. This is the most prudent approach given lack of long-term human data.

If my injury still isn't healed after one cycle, should I immediately start another?

Not immediately. Take a 2-4 week break, reassess progress, and identify barriers to healing (inadequate physical therapy, continued re-injury, comorbidities). If barriers are addressed, restart a second cycle. If no additional improvement occurs, the issue may not be peptide-responsive.

How many cycles can I do in a year?

2-4 cycles per year (8-32 weeks annual exposure) is reasonable. More than 4 cycles suggests you're using BPC-157 for nearly continuous healing, which either indicates a serious underlying injury or over-reliance on the peptide. Investigate why healing isn't completing between cycles.

Can I use BPC-157 preventively before injury occurs?

There is no evidence this works or that it is safe. BPC-157's benefits are observed in the context of tissue damage. Using it to "pre-strengthen" healthy tissue is speculative. Focus on injury prevention through proper training, nutrition, and rest.

Should I taper BPC-157 doses at the end of a cycle, or just stop abruptly?

Abrupt discontinuation is fine. BPC-157 does not create withdrawal or rebound effects. Stop when your cycle is complete. No tapering is necessary or beneficial.